Bioventus Inc. (BVS) Tops Q2 EPS by 14c ; Offers Guidance

Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.14, $0.14 better than the analyst estimate of $0.00. Revenue for the quarter came in at $137.1 million versus the consensus estimate of $129.23 million.

GUIDANCE:

Bioventus Inc. sees Q3 2023 EPS of ($0.24)-($0.20), versus the consensus of ($0.56). Bioventus Inc. sees Q3 2023 revenue of $490-505 million, versus the consensus of $493.3 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance